Trial Profile
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, A Single-Arm, Phase II Study (ALPHA Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ALPHA
- 19 Apr 2022 Status changed from active, no longer recruiting to completed.
- 19 Jan 2022 Results published in the Clinical Cancer Research
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology